Genmab cancer medication in new promising showing

Biotech form eyeing further approval of medication against multiple myeloma

The Danish biotech company Genmab is nearing a new victory in its battle against cancer following promising clinical results for Daratumumab, its medication against multiple myeloma, the most common type of bone marrow cancer.

Daratumumab, which is sold as Darzalex and has been approved only in the US as of now, fulfilled all of its goals in a considerable study during which the cancer returned after being treated by other medications.

“We are very pleased with the positive interim result in this study, which documents the therapeutic potential of daratumumab in combination with bortezomib and dexamethasone,” said Jan van de Winkel, the CEO of Genmab.

“We look forward to having the data presented at a future major medical conference.”

READ MORE: US authorities approve Danish cancer drug

Hoping for further approval
In total, daratumumab was administered to 490 patients along with either bortezomib, a type of chemotherapy, or dexamethason, another form of cancer treatment.

The results were so effective that the study was ended prematurely, which is something typically done if there is an effect that can save the lives of patients considered terminal.

Daratumumab is already approved for the treatment of patients with multiple myeloma who have undergone three previous treatments, but Genmab hopes the new study will help the medication to obtain approval for other treatment types.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.